Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nanoparticle Reagent Simplifies Gene Expression Programming

By LabMedica International staff writers
Posted on 13 Sep 2017
Novel nanoparticle carriers were used to deliver mRNA directly to specific cell types (T-cells of the immune system and blood stem cells) in order to induce short-term changes in gene expression that could be harnessed to treat diseases ranging from cancer to diabetes.

Therapies based on immune cells have been applied for a variety of diseases. More...
However, the viral and electroporation methods used to create such cytoreagents are complex and expensive. Therefore, investigators at the Fred Hutchinson Cancer Research Center (Seattle, WA, USA) developed targeted mRNA nanocarriers that were simply mixed with cells to reprogram them via transient gene expression. The nanoparticles were loaded with a gene-editing tool that snipped out natural T-cell receptors, and then was paired with genes encoding a "chimeric antigen receptor" or CAR, a synthetic molecule designed to attack cancer cells. Ultimately, the nanoparticles were removed from the body like other cell waste.

This approach was called "hit-and-run" genetic programming, since the transient effect of mRNA did not change the DNA, but it was enough to make a permanent impact on the cells' therapeutic potential.

In the August 30, 2017, online edition of the journal Nature Communications the investigators described three examples that they had used to establish that the approach was simple and generalizable. First, they demonstrated that nanocarriers delivering mRNA encoding a genome-editing agent could efficiently knockout selected genes in anti-cancer T-cells. Second, they imprinted a long-lived phenotype exhibiting improved antitumor activities into T-cells by transfecting them with mRNAs that encoded a key transcription factor of memory formation. Third, they showed how mRNA nanocarriers could program hematopoietic stem cells with improved self-renewal properties.

"Our goal is to streamline the manufacture of cell-based therapies," said senior author Dr. Matthias Stephan, a biomaterials expert at the Fred Hutchinson Cancer Research Center. "In this study, we created a product where you just add it to cultured cells and that is it -- no additional manufacturing steps. We developed a nanocarrier that binds and condenses synthetic mRNA and protects it from degradation. Just add water to our freeze-dried product. If you know from the scientific literature that a signaling pathway works in synergy, you could co-deliver mRNA in a single nanoparticle. Every cell that takes up the nanoparticle can express both."

Related Links:
Fred Hutchinson Cancer Research Center


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.